Last update Aug. 12, 2019
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Κινναριζίνη is Cinnarizine in Greek.Is written in other languages:
Κινναριζίνη belongs to this group or family:
Main tradenames from several countries containing Κινναριζίνη in its composition:
|Tmax||1 - 3||hours|
|T½||3 - 24||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A calcium channel blocker drug and an antihistamine piperazine derivative which has a sedative effect. Chemical structure and effects similar to Flunarizine.
Used to treat nausea and vertigo of Meniere's Disease, and symptoms of Traveler´s Sickness.
It has been withdrawn from the market in several countries because of Parkinson-like symptoms (Teive 2004, Martí 1985).
At latest update relevant published data were not found on excretion into breast milk.
Its high binding capacity to plasma proteins makes it unlikely excretion into breastmilk.
It should be wise on the long-term, the use of a known safer alternative until more data is available on this drug, mostly for children in the neonatal period or in case of prematurity that may be affected by an increased gut permeability. Occasional use to prevent motion sickness may be compatible with breastfeeding.
See below the information of this related product: